According to industry executives, this partnership signals Ciplas strong commitment to investing in innovative metabolic therapies and amplifying on GLP-1 receptor agonists as a cornerstone for future growth
Wegovy is approved for chronic weight management if you are overweight with a BMI (body mass index) of 30 or higher, or a BMI of 27 or above and at least one related health condition, including: High blood pressure, type 2 diabetes, or high cholesterol
The dose starts small and gradually increases over several weeks, primarily to reduce the side effects of nausea, diarrhea, constipation, abdominal pain, and bloating
However, its important to know that how it works the effects of the GLP-1 hormone in the body and how semaglutide affects weight loss is essential to recognizing its potential for meaningful and positive effects
Dietary modifications are fundamental to reducing gastrointestinal symptoms